Borderline Mucinous Tumor Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A rare case of an androgen-secreting mucinous borderline ovarian tumour in a perimenopausal woman
Br J Hosp Med (Lond). 2022 Apr 2;83(4):1-5. doi: 10.12968/hmed.2021.0377. Epub 2022 Apr 29.NO ABSTRACTPMID:35506727 | DOI:10.12968/hmed.2021.0377 (Source: British Journal of Hospital Medicine)
Source: British Journal of Hospital Medicine - May 4, 2022 Category: Internal Medicine Authors: Kyle Cilia Jessica Mangion Miriam G Imbroll Mark Gruppetta Source Type: research

Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?
Conclusions: This is the largest series of long-term survivors with histologically confirmed PDAC. With upfront resection and adjuvant therapy an actual overall 5YS rate of 18.8% can be expected. in favorable subgroups actual 5YS is above 50%. (Source: Annals of Surgery)
Source: Annals of Surgery - May 1, 2022 Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research

Endocrine cell micronests in an ovarian mucinous borderline tumor: a potential diagnostic pitfall for microinvasion
The occurrence of endocrine cell micronests in ovarian tumors is rarely reported. To our knowledge, there are only three prior cases reported to date: one occurring in an ovarian mucinous cystadenoma, one in a... (Source: Diagnostic Pathology)
Source: Diagnostic Pathology - April 14, 2022 Category: Pathology Authors: Katrina Collins, Sheila Segura and Michael Hwang Tags: Case Report Source Type: research

Cancers, Vol. 14, Pages 1485: Fertility Sparing Surgery and Borderline Ovarian Tumours
aso Joseph Yazbek To determine the oncological outcomes following fertility-sparing surgery (FSS) for the management of Borderline Ovarian Tumours (BOTs). A retrospective analysis of participants diagnosed with BOTs between January 2004 and December 2020 at the West London Gynaecological Oncology Centre was conducted. A total of 172 women were diagnosed; 52.3% (90/172) underwent FSS and 47.7% (82/172) non-FSS. The overall recurrence rate of disease was 16.9% (29/172), of which 79.3% (23/29) presented as the recurrence of serous or sero-mucinous BOTs and 20.7% (6/29) as low-grade serous carcinoma (LGSC). In the FSS gr...
Source: Cancers - March 14, 2022 Category: Cancer & Oncology Authors: Lorraine S. Kasaven Mehar Chawla Benjamin P. Jones Maya Al-Memar Nicolas Galazis Yousra Ahmed-Salim Mona El-Bahrawy Stuart Lavery Srdjan Saso Joseph Yazbek Tags: Article Source Type: research